Axel Merseburger
banner
axelmerseburger.bsky.social
Axel Merseburger
@axelmerseburger.bsky.social
Urologist
Reposted by Axel Merseburger
Can investigational treatments address unmet needs in mCRPC, and what are the barriers to uptake of clinical practice guidelines? Get answers with expert opinions from @axelmerseburger.bsky.social and @neerajagarwal.bsky.social on the latest in mCRPC management #MedSky #MedEd

ow.ly/xIiE50W8qk2
June 12, 2025 at 3:03 PM
Reposted by Axel Merseburger
Listen to @sfreedlandmd.bsky.social and @axelmerseburger.bsky.social discuss personalised medicine, molecular testing, and improving patient quality of life in #mCRPC with NEW podcast episodes #ProstateCancer #Oncology #Podcast #MedSky #MedicalEducation #MedEd

ow.ly/pQWx50W2IAp
June 2, 2025 at 3:52 PM
Reposted by Axel Merseburger
Can a shingles vaccine protect the brain?
Zoster vaccination linked to a 20% lower risk of dementia over 7 years.
@nature.com
rdcu.be/egydp
April 6, 2025 at 4:21 PM
Reposted by Axel Merseburger
Proud to be one of the investigators: #MicroUS noninferior to MRI fusion for csPCa (46.1% vs 42.6%)! No MRI, slightly better results. 802 pts, 8 countries. Just presented #EAU25 and published in #JAMA. #ProstateCancer #biopsy @axelmerseburger.bsky.social
March 24, 2025 at 11:38 AM
Reposted by Axel Merseburger
LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social
March 24, 2025 at 11:36 AM
Reposted by Axel Merseburger
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication

www.fda.gov/drugs/resour...

FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI
FDA expands Pluvicto’s prostate cancer indication
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto).
www.fda.gov
March 31, 2025 at 8:50 AM
Reposted by Axel Merseburger
🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger
@axelmerseburger.bsky.social
February 8, 2025 at 2:38 PM
🚀 Who are the top oncologists leading the digital conversation?

📢 Check out this ranking of digital thought leaders in oncology based on their Twitter following!

📊 Notably, female oncologists highlighted in green! 👇 #GU25 #ASCOGU25
February 5, 2025 at 1:20 PM
Reposted by Axel Merseburger
🎉 Great News! 🎉

I am delighted that we received a total of 4 awards in the renowned Focus Clinic List, thanks to the tremendous support from the entire team at the Urology Clinic!

Our recognitions include: 
- #BladderCancer
- #ProstateCancer
- #KidneyCancer
- #Oncology
January 25, 2025 at 10:47 AM
🎉 Great News! 🎉

I am delighted that we received a total of 4 awards in the renowned Focus Clinic List, thanks to the tremendous support from the entire team at the Urology Clinic!

Our recognitions include: 
- #BladderCancer
- #ProstateCancer
- #KidneyCancer
- #Oncology
January 25, 2025 at 10:47 AM
Reposted by Axel Merseburger
Immunotherapy shows sex bias—men respond better; women face more severe AEs. Understanding sex hormones, chromosomes, and epigenetics in immunity could lead to tailored immuno-oncology strategies. #Cancer #Immunotherapy #Oncology @oncoalert.bsky.social
rdcu.be/d49Mq
December 30, 2024 at 7:14 AM
Merry Christmas 🎄🎅🎁 #firstpostonbluesky #Lübeck
December 26, 2024 at 8:20 AM
Reposted by Axel Merseburger
Ich verlasse nicht nur die Uni #Magdeburg, sondern auch #X – weil es jetzt einfach reicht!
Ab sofort findet ihr mich hier und unter logicuro.com
@axelmerseburger.bsky.social
December 19, 2024 at 10:36 PM